Eighteen U.S.-listed companies that completed IPOs in 2013 are down a median of 2% since their 180-day lockup periods expired. Taking into account the strong performance of the biotech industry in 2013, the group is down a median of 4% post-lockup relative to the BioCentury 100 index.

From the IPO date, the group is up 38%, or up 7% compared with the BC100.